Compare SYSCO Corporation (SYY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs Tango Therapeutics Inc. — how do they compare? SYSCO Corporation trades at $80.81 (market cap $38.88B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: SYSCO Corporation is far larger — about 10.4× Tango Therapeutics Inc.'s market cap, and SYSCO Corporation pays a 2.78% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold SYSCO Corporation for 78 Days and Tango Therapeutics Inc. for 0 Days on average.
| SYY | TNGX | |
|---|---|---|
Market Cap | $38.88B | $3.75B |
Volume | 2,477,462 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $32.90 |
52-Week Low | $69.30 | $7.50 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $52.06B | $2.77B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYY trades at $80.97, up 2.88% with a bearish technical signal despite recent earnings beats. The company maintains steady revenue growth, reaching $81.37B in 2025, with strong profitability metrics including 78.16% ROE. Recent developments include a $500M AI efficiency program and a $1.5B senior notes offering. Analyst consensus remains positive with 60% buy ratings and an $85.75 price target, though technical indicators show resistance near $79-80 levels.
SYY presents a mixed outlook with strong fundamentals offset by technical weakness. The stock offers value with a 0.45 P/S ratio and dividend yield, supported by consistent revenue growth and AI-driven efficiency initiatives. Key risks include high debt levels at 49.75% debt-to-asset ratio and margin pressure as net income margin declined to 2.08%. Institutional ownership trends positive with recent pension fund increases.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
